Uncertain miracle: a biotech drug extends a life, but at what price? For Ms. Lees, treatment bill now totals $7 million; her bones keep crumbling; guilt of another $1,400 day.

出版信息

Wall St J (East Ed). 2005 Nov 16:A1, A15.

Abstract

摘要

相似文献

Uncertain miracle: a biotech drug extends a life, but at what price? For Ms. Lees, treatment bill now totals $7 million; her bones keep crumbling; guilt of another $1,400 day.

Wall St J (East Ed). 2005 Nov 16:A1, A15.

Why Genzyme can charge so much for Cerezyme.

Wall St J (East Ed). 2005 Nov 16:A15.

Lucrative niches: how drugs for rare diseases became lifeline for companies.

Wall St J (East Ed). 2005 Nov 15:A1, A18.

No price too high?

N Engl J Med. 1992 Dec 3;327(23):1676-8. doi: 10.1056/NEJM199212033272310.

Drug development. Orphan drug windfalls?

Nature. 1992 Jan 30;355(6359):381. doi: 10.1038/355381b0.

Creating the costliest orphan. The Orphan Drug Act in the development of Ceredase.

Int J Technol Assess Health Care. 1992 Fall;8(4):583-97. doi: 10.1017/s0266462300002294.

[Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary].

Orv Hetil. 2014 Nov 2;155(44):1735-41. doi: 10.1556/OH.2014.30031.

Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario.

CMAJ. 2001 Sep 4;165(5):595-6.

[Financing of enzyme treatment in Gaucher disease].

Tidsskr Nor Laegeforen. 2003 Feb 6;123(3):364.

Support system: through charities, drug makers help people--and themselves.

Wall St J (East Ed). 2005 Dec 1:A1, A10.

引用本文的文献

The legal imperative for treating rare disorders.

Orphanet J Rare Dis. 2013 Sep 6;8:135. doi: 10.1186/1750-1172-8-135.

On specialty pharmaceuticals: reflections of a second-year medical student.

Biotechnol Healthc. 2006 Oct;3(5):41-4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验